ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,927Medicare Part D Prescriptions Filled, Including Refills

Rank: 139 out of 617

$533K Total Retail Price of All Prescriptions

Rank: 79 out of 617

340 Patients Receiving at Least One Drug in Part D
68%Patients 65 Years and Older
57% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nebraska
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 340 patients filled at least one prescription for a schedule two drug, compared to an average of 5%.

Schedule Three
Controlled Substances

19% of this provider’s 340 patients filled at least one prescription for a schedule three drug, compared to an average of 11%.

Risky Drugs to Seniors

1% of this provider’s 5,772 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$60 was the average price of a prescription from this provider, compared to $49 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nebraska
SIMVASTATIN 393 286 1 2
LEVOTHYROXINE SODIUM 295 224 2 1
HYDROCODONE-ACETAMINOPHEN 276 119 S3 3 8
OMEPRAZOLE 271 180 4 3
METFORMIN HCL ER 259 157 5 72
WARFARIN SODIUM 169 161 6 7
ATORVASTATIN CALCIUM 162 153 7 14
LISINOPRIL 158 96 8 5
METOPROLOL SUCCINATE 156 105 9 12
FUROSEMIDE 147 124 10 4
GLIMEPIRIDE 138 87 11 33
AMLODIPINE BESYLATE 132 70 12 6
CRESTOR 130 90 13 28
ZOLPIDEM TARTRATE 129 85 14 23
MELOXICAM 121 96 15 24
ALLOPURINOL 119 102 16 27
POTASSIUM CHLORIDE 107 91 17 10
ATENOLOL 106 58 18 17
TRAMADOL HCL 101 70 19 15
LANTUS 93 57 20 39
RAMIPRIL 90 79 21 67
CITALOPRAM HBR 87 82 22 18
NEXIUM 85 52 23 43
TAMSULOSIN HCL 85 84 23 26
CYMBALTA 85 26 23 49
ADVAIR DISKUS 75 37 26 38
PREMARIN 74 26 R 27 108
PROAIR HFA 74 33 27 75
CYCLOBENZAPRINE HCL 72 14 R 29 74
HYDROCHLOROTHIAZIDE 72 46 29 13
SULFAMETHOXAZOLE-TRIMETHOPRIM 71 47 31 91
SERTRALINE HCL 71 54 31 20
METFORMIN HCL 70 47 33 9
CARVEDILOL 68 59 34 19
METOPROLOL TARTRATE 66 57 35 11
CLOPIDOGREL 64 56 36 53
TRICOR 59 45 37 83
PREDNISONE 58 30 38 31
PANTOPRAZOLE SODIUM 58 37 38 37
OXYCODONE-ACETAMINOPHEN 56 27 S2 40 93
DONEPEZIL HCL 54 54 41 30
ALENDRONATE SODIUM 53 48 42 25
TRAZODONE HCL 53 34 42 51
PROPRANOLOL HCL 51 0 44 109
VENTOLIN HFA 51 0 44 200
FAMOTIDINE 50 29 46 54
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on June 19, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.